Akouos
Latest round
- Series B
Last raised
- Feb 2020
Total raised
- $138M
Investors
- 16
About Akouos
Akouos, Inc.Founded in 2016 in Boston, US, Akouos, Inc. develops gene therapies to address hearing loss.00 mn. Their most recent deal occurred on June 25, 2020, involving an acquisition by Eli Lilly and Company for approximately USD 610 mn.Akouos focuses on developing precision genetic therapies to restore, improve, and preserve hearing for individuals with disabling hearing loss. Their products utilize advanced gene therapy technologies to target genetic causes of hearing loss, with an aim to deliver effective clinical treatments for patients.40 mn. The company's revenue model is based on partnerships and direct transactions with healthcare providers for gene therapy products, ensuring streamlined access to their offerings to meet healthcare needs.Following the acquisition by Eli Lilly and Company, Akouos plans to use the funds to advance its lead program, AK-OTOF, into first-in-human clinical studies and establish in-house GMP manufacturing capabilities at its new Boston Seaport office. The company aims to accelerate the development of pipeline programs addressing other forms of sensorineural hearing loss and expand its team in research and clinical development.
Who invested in Akouos
16 investors across 3 rounds
See all investors in Akouos
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Akouos
Who invested in Akouos?
Akouos has 16 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Akouos raised?
Akouos has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Akouos last raise money?
Akouos's most recent round on record is a Series B, in Feb 2020.
What does Akouos do?
Akouos is a biotechnology company.
Where is Akouos headquartered?
Akouos is headquartered in Boston, US.
Which VCs invest in companies like Akouos?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Akouos's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Akouos? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.